Navigation Links
What U.S. Doctors Know That Has Not Yet Reached China
Date:10/22/2013

NEW YORK, Oct. 22, 2013 /PRNewswire/ -- Fibromyalgia (FM), a disorder now taken seriously in the United States after decades of misinformation and misdiagnosis, is still largely misunderstood and underdiagnosed by physicians in China. A recent national survey of Chinese rheumatologists revealed they have a lower awareness of FM compared with colleagues in Western countries. Sadly for China's patients with FM—a chronic disorder characterized by widespread musculoskeletal pain and fatigue—the dismissive attitude formerly directed at U.S. patients ("It's all in your mind!") is now being encountered by Chinese patients, just before they walk out of the doctor's office with no relief in sight.

An anonymous survey was conducted among a nationwide sample of Chinese rheumatologists at the 15th National Rheumatology Conference in 2010, with results published in the International Journal of Rheumatic Diseases this year. Of more than 700 respondents, 80 percent reported difficulties in treating FM patients. Nearly all—90.8 percent—mistakenly believed that the prognosis of FM patients was usually benign, and nearly 30 percent believed FM was only a psychological disorder. The investigators concluded that "awareness and perception of FM are still low among Chinese rheumatologists." There was some good news from the survey, however: "Our data also showed that most Chinese rheumatologists were eager for continuing medical education on FM."

In the U.S., people with FM who complained of "pain all over their bodies, constant fatigue and poor sleep" are no longer being told all they have is a psychological condition. Thanks to advanced medical technologies, most doctors here—both rheumatologists and other specialists—now have a deeper understanding as to how FM affects the body. However, with five million affected people in the U.S., the challenge is that treatment remains elusive. And there are still outstanding challenges as only half of this population is being treated.

Enter Seth Lederman, M.D., President and CEO of NYC-based TONIX Pharmaceuticals. The company's formulation, TNX-102 SL, is designed to help change FM treatment for millions of sufferers. Dr. Lederman and his team believe the key to easing the pain and suffering is enabling these patients to break the vicious cycle between poor sleep at night and pain during the day.

TONIX has taken cyclobenzaprine—an FDA-approved muscle relaxant that's been on the market for 35 years—and reformulated it as an under-the-tongue tablet taken at bedtime. This allows cyclobenzaprine to be taken up into the bloodstream rapidly, setting the tone for restorative sleep, which has been shown to mitigate pain experienced in FM.

Tonix recently announced the initiation of its Bedtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) clinical trial, which is the first of two pivotal trials for TNX-102 SL 2.8 mg tablets, in patients with FM. 

For more on TNX-102 SL and the BESTFIT trial, visit www.tonixpharma.com.

Contact:  Laura Radocaj, Dian Griesel Int'l., 212.825.3210


'/>"/>
SOURCE TONIX Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Scripps Doctors Study Novel New Device to Diagnose Irregular Heart Beat
2. Denver Patients Can Now Easily Find Doctors and Schedule Appointments Online
3. Doctors at St. Josephs Hospital Stopping Atrial Fibrillation Cold
4. New Program Has Doctors, Patients Learn Together As Traditional Relationship Changes Forever
5. Eaton Scientific Discusses Positive Anecdotal Feedback from Pharmacist Compounding Homatropine for Doctors Treating Patients Experiencing Hot Flash Symptoms in the Beverley Hills and Los Angeles Area.
6. Latest Trend in Drug Manufacturer Sales Allows Doctors to Obtain Product Samples Online
7. Africa Needs Engineers as Much as Doctors to Save Lives, says South African Entrepreneur
8. Africa Needs Engineers as Much as Doctors to Save Lives, says South African Industrialist
9. The Japanese Cancer Association and Debiopharm Group Present Doctors Oshima and Tanaka with the 2012 JCA-Mauvernay Award for their Innovative and Outstanding Cancer Research
10. WebMD Study: U.S. Doctors Deeply Divided on Many Matters of Ethical Ambiguity
11. For Drug Manufacturers Bringing a New Product to Market, Gaining the Support of Influential Doctors Is a Mission-Critical Priority
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Halo Labs announces the European launch of their new ... at MIBio 2017 in Cambridge, U.K on ... in biopharmaceutical samples with unprecedented speed and sensitivity while using far ... Membrane Imaging. ... particle analysis system ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The ... to promote standards of excellence for the field of eating disorders, announces the ... – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
Breaking Medicine News(10 mins):